<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264341</url>
  </required_header>
  <id_info>
    <org_study_id>HE 21/10</org_study_id>
    <secondary_id>2010-020664-38</secondary_id>
    <nct_id>NCT01264341</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma</brief_title>
  <official_title>Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of bevacizumab/temsirolimus
      is effective in patients with advanced renal carcinoma progressing after anti-VEGF treatment
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on the developments in the treatment of recurrent metastatic renal cancer, the study
    treatment is no longer considered to be the best treatment option
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month Progression Free Survival (PFS)</measure>
    <time_frame>32 months</time_frame>
    <description>Proportion of patients who are progression-free at 6month evaluation from treatment initiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Tumor assessments will be performed every 8 weeks during treatment and at discontinuation, unless it was performed within the last 4 weeks</time_frame>
    <description>PFS will be calculated from date of treatment initiation until disease progression or death (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>48 months</time_frame>
    <description>OS will be calculated from the date of treatment initiation to the date of death or last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>Tumor assessments will be performed every 8 weeks during treatment and at discontinuation, unless it was performed within the last 4 weeks</time_frame>
    <description>RR is defined as the overall percentage of patients with partial (PR) or complete response (CR). The evaluation of responses will be performed according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Shrinkage</measure>
    <time_frame>Tumor assessments will be performed every 8 weeks during treatment and at discontinuation, unless it was performed within the last 4 weeks</time_frame>
    <description>Tumor shrinkage will be computed using waterfall plots</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) of all participants will be recorded and assessed upon signature of the informed consent form, until 30 days after the last administration of study treatment.</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse Events will be graded according to the NCI CTCAE v3.0 criteria and will be reported in a frequency table according to the highest severity grade observed per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) assessment</measure>
    <time_frame>At baseline and every 8 weeks during treatment</time_frame>
    <description>QoL will be assessed using the EORTC QLQ C-30 questionnaire. The change in the QoL during treatment will be estimated using the Wilcoxon paired t-test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of antiangiogenic factors (FGF, VEGF, VEGFRR)</measure>
    <time_frame>36 months</time_frame>
    <description>Changes in serum levels of antiangiogenic factors during treatment and correlation to the outcome of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab combined with temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.</description>
    <arm_group_label>Bevacizumab combined with temsirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.</description>
    <arm_group_label>Bevacizumab combined with temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18th year of age completed)

          -  Signed and dated written informed consent form prior to any procedures related to this
             protocol.

          -  Histologically confirmed advanced clear cell renal cancer.

          -  Measurable disease.

          -  Failure of first line anti-VEGF treatment.

          -  Performance status 0-2, according to Eastern Cooperative Oncology Group (ECOG) .

          -  Satisfactory hematological parameters:

               -  White blood cell count &gt; 4000 mm3.

               -  Platelet count 100000/mm3.

               -  Neutrophil blood cell count &gt; 1200/ mm3 .

               -  Hemoglobin &gt; 9,0 g/dL (can be achieved with red blood cell transfusion).

          -  Satisfactory biochemical parameters:

               -  Serum creatinine &lt; 2 x Upper Limit of Normal(ULN)

               -  Aspartate Aminotransferase (AST)&lt;2,5 x ULN

               -  Alanine Transaminase (ALT)&lt; 2,5 x ULN.

               -  Bilirubin &lt;2 x ULN

          -  (For female patients) Absence of pregnancy (negative pregnancy test for women of
             reproductive age before enrollment).

          -  (For female patients) Non-lactating women.

          -  Use of efficient contraceptive measures (women and men) to prevent possible pregnancy
             of female patient or female partner of a male patient during treatment and until 6
             months after the end of treatment.

        Exclusion Criteria:

          -  Prior treatment with mTOR inhibitor.

          -  Major surgery (including open biopsy) or insufficient recovery or existence of major
             trauma within 4 weeks before enrollment.

          -  Uncontrolled hypertension.

          -  Active infection requiring systemic treatment within 4 weeks prior to enrollment.

          -  Minor surgery (for instance, catheter placement) within 2 days before enrollment.

          -  Scheduled major surgery within the treatment period.

          -  Medical history in the last 6 months prior to enrollment of significant cardiovascular
             disease, diabetes, cardiac infarction, unstable angina, uncontrolled arrhythmia or
             significant heart failure.

          -  Indications of uncontrolled metastases or disease progression in CNS lesions (the
             suspicion of uncontrolled metastases or disease progression should be eliminated by
             imaging techniques within 14 days prior to enrollment).

          -  Medical history in the last 5 years prior to enrollment of any other malignancies
             (excluding the basal or squamous skin cell carcinoma or in situ carcinoma of the
             cervix).

          -  History of non-healing wound including active gastric ulcer.

          -  History of fistula in the last 6 months prior to enrollment.

          -  History of gastrointestinal perforations.

          -  Patient incapacity (for psychiatric or social reasons) to conform with the protocol.

          -  History of hemorrhagic predisposition.

          -  History of hypersensitivity to the medications under investigation.

          -  Significant proteinurea.

          -  Prior immunotherapy within 4 weeks prior to enrollment.

          -  Prior radiation treatment within 2 weeks prior to enrollment.

          -  Concomitant medication with inducers or strong inhibitors of the coenzyme CYP3A4 (see
             Appendix 5 for an indicative list of active compounds).

          -  Concurrent participation in other interventional clinical trials with investigational
             medicinal products.

          -  History of chronic interstitial lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aristotelis Bamias, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>General Peripheral Hospital of Athens &quot;Alexandra&quot;, Medical School, University of Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Hippokratio&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Peripheral Hospital of Athens &quot;Alexandra&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agii Anargiri Cancer Hospital, 2nd Dept of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, 1st Dept of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, 2nd Dept of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Rio, Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

